Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

Abstract Background Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. During tre...

Description complète

Détails bibliographiques

Auteurs principaux:	Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2021-07-01
Collection:	BMC Pulmonary Medicine
Sujets:	Antifibrotic therapy Idiopathic pulmonary fibrosis Switch of antifibrotics
Accès en ligne:	https://doi.org/10.1186/s12890-021-01587-3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!